ABP 215 (Bevacizumab-awwb), a Bevacizumab (HY-P9906) biosimilar, is a humanized IgG1 monoclonal antibody targeting VEGFA. ABP 215 has anticancer effects, and can be used metastatic colorectal cancer (mCRC) research[1][2].
CAS Number:
[1438851-35-4]
Target:
VEGFR
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted